Søgeresultater - Jim Cassidy

  • Showing 1 - 15 results of 15
Refine Results
  1. 1
    The Evolution of Fluoropyrimidine Therapy: From Intravenous to Oral

    The Evolution of Fluoropyrimidine Therapy: From Intravenous to Oral af Paulo M. Hoff, Jim Cassidy, Hans‐Joachim Schmoll

    Udgivet 2001
    Få fuldtekst Få fuldtekst
    Revisão
    Føj til favoritter
    Saved in:
  2. 2
    Striking the right balance in colorectal cancer care--a qualitative study of rural and urban patients

    Striking the right balance in colorectal cancer care--a qualitative study of rural and urban patients af Norma Bain, Neil Campbell, Lewis Ritchie, Jim Cassidy

    Udgivet 2002
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  3. 3
    Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancer

    Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancer af Natividad Gomez-Roman, Neha M. Sahasrabudhe, Fiona McGregor, Anthony J. Chalmers, Jim Cassidy, Jane A. Plumb

    Udgivet 2016
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  4. 4
    A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer

    A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer af N. Steele, A Anthony, Mark Saunders, B. Esmarck, E. Ehrnrooth, Paul E.G. Kristjansen, Annsofi Nihlén, L T Hansen, Jim Cassidy

    Udgivet 2012
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  5. 5
    Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients

    Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients af Jim Cassidy, Leonard B. Saltz, Chris Twelves, Eric Van Cutsem, Paulo M. Hoff, Yoon‐Koo Kang, Jasmine Saini, Frank Gilberg, David Cunningham

    Udgivet 2011
    Få fuldtekst Få fuldtekst
    Revisão
    Føj til favoritter
    Saved in:
  6. 6
    Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803

    Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Dat... af Daniel J. Sargent, Qian Shi, Greg Yothers, Eric Van Cutsem, Jim Cassidy, Leonard B. Saltz, Norman Wolmark, Brian M. Bot, Axel Grothey, Marc Buyse, Aimery de Gramont

    Udgivet 2011
    Få fuldtekst
    Revisão
    Føj til favoritter
    Saved in:
  7. 7
    Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials

    Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials af Hendrik‐Tobias Arkenau, Dirk Arnold, Jim Cassidy, Eduardo Díaz‐Rubio, Jean‐Yves Douillard, Howard S. Höchster, Andrea Martoni, Axel Grothey, Axel Hinke, Wolff Schmiegel, Hans‐Joachim Schmoll, Rainer Porschen

    Udgivet 2008
    Få fuldtekst Få fuldtekst
    Revisão
    Føj til favoritter
    Saved in:
  8. 8
    Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer

    Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer af Jim Cassidy, Stephen Clarke, Eduardo Díaz‐Rubio, Werner Scheithauer, Arié Figer, Ralph Wong, Sheryl Koski, Mikhail Lichinitser, Tsai‐Shen Yang, Fernando Rivera, Félix Couture, Florin Sirzén, Leonard B. Saltz

    Udgivet 2008
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  9. 9
    Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

    Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study af Leonard B. Saltz, Stephen Clarke, Eduardo Díaz‐Rubio, Werner Scheithauer, Arié Figer, Ralph Wong, Sheryl Koski, Mikhail Lichinitser, Tsai‐Shen Yang, Fernando Rivera, Félix Couture, Florin Sirzén, Jim Cassidy

    Udgivet 2008
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  10. 10
    XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer

    XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer af Jim Cassidy, Josep Tabernero, Chris Twelves, René Brunet, Charles Butts, Thierry Conroy, Filippo de Braud, Arié Figer, Johannes Grossmann, Noriaki Sawada, Patrick Schöffski, Alberto Sobrero, Eric Van Cutsem, Eduardo Díaz‐Rubio

    Udgivet 2004
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  11. 11
    First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin

    First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin af Jim Cassidy, Chris Twelves, Eric Van Cutsem, Paulo M. Hoff, Emilio Bajetta, Michael Boyer, R. Bugat, Ulrich Bürger, A. Garin, Ullrich Graeven, J. McKendrick, Jean A. Maroun, John L. Marshall, B Osterwalder, G. Pérez-Manga, R. Rosso, P. Rougier, Richard L. Schilsky

    Udgivet 2002
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  12. 12
    Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial

    Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial af Werner Scheithauer, J McKendrick, S. Begbie, Markus Borner, W. Ivon Burns, Howard A. Burris, Jim Cassidy, Duncan I. Jodrell, P. Koralewski, E.L. Levine, Norbert Marschner, Jean A. Maroun, Pilar García‐Alfonso, Jerzy Tujakowski, Guy van Hazel, A. Wong, J. Załuski, Chris Twelves

    Udgivet 2003
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  13. 13
    Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines

    Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines af Daniel G. Haller, Jim Cassidy, Stephen Clarke, David Cunningham, Eric Van Cutsem, Paulo M. Hoff, Mace L. Rothenberg, Leonard B. Saltz, Hans‐Joachim Schmoll, Carmen J. Allegra, Joseph R. Bertino, Jean-Yves Douillard, Bengt Gustavsson, G. Milano, Michael J. OʼConnell, Youcef M. Rustum, Josep Tabernero, Frank Gilberg, Florin Sirzén, Chris Twelves

    Udgivet 2008
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  14. 14
    Capecitabine as Adjuvant Treatment for Stage III Colon Cancer

    Capecitabine as Adjuvant Treatment for Stage III Colon Cancer af Chris Twelves, A. Wong, Marek P. Nowacki, Markus Abt, Howard A. Burris, Alfredo Carrato, Jim Cassidy, Andrés Cervantes, Jan Fagerberg, Vassilis Georgoulias, Fares Husseini, Duncan I. Jodrell, P. Koralewski, H. Kröning, Jean A. Maroun, Norbert Marschner, Joseph McKendrick, Marek Pawlicki, Riccardo Rosso, Johannes Schüller, Jean‐François Seitz, Borut S̆tabuc, Jerzy Tujakowski, Guy van Hazel, J. Załuski, Werner Scheithauer

    Udgivet 2005
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  15. 15
    3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

    3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial af Timothy Iveson, Rachel Kerr, Mark Saunders, Jim Cassidy, Niels Henrik Holländer, Josep Tabernero, Andrew Haydon, Bengt Glimelius, Andrea Harkin, Karen Allan, John McQueen, Claire Scudder, Kathleen Boyd, Andrew Briggs, Ashita Waterston, Louise Medley, Charles B. Wilson, Richard Ellis, Sharadah Essapen, A.S. Dhadda, Mark Harrison, Stephen Falk, Sherif Raouf, Charlotte Rees, Rene K Olesen, David Propper, John Bridgewater, Ashraf Azzabi, David Farrugia, Andrew Webb, David Cunningham, Tamas Hickish, Andrew Weaver, Simon Gollins, Harpreet Wasan, James Paul

    Udgivet 2018
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:

Søgeredskaber: